Acadian Asset Management LLC Kinnate Biopharma Inc. Transaction History

Acadian Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.24 - $2.66 $301,029 - $357,472	134,388 Added 16.18%	964,881 $2.57 Million
Q4 2023 Feb 13, 2024	BUY	$1.07 - $2.5 $100,373 - $234,517	93,807 Added 12.73%	830,493 $1.97 Million
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $422,119 - $1.01 Million	305,884 Added 71.0%	736,686 $1.03 Million
Q2 2023 Aug 07, 2023	BUY	$2.33 - $6.84 $936,396 - $2.75 Million	401,887 Added 1389.89%	430,802 $1.3 Million
Q1 2023 May 11, 2023	BUY	$3.46 - $7.98 $62,034 - $143,073	17,929 Added 163.2%	28,915 $179,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $14,885 - $34,497	2,830 Added 34.7%	10,986 $67,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $25,734 - $41,133	-2,610 Reduced 24.24%	8,156 $97,000
Q2 2022 Aug 09, 2022	BUY	$7.43 - $13.0 $79,991 - $139,958	10,766 New	10,766 $136,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.